Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1442134 | 0.79 | BTK (0.33) | ADORA2AKMT2AMEN1BTKADORA1 | |
| SCHEMBL1443295 | 0.78 | BTK (0.33) | ADORA2AL3MBTL1KMT2AALDH1A1BTK | |
| SCHEMBL1441720 | 0.78 | HTT (0.34) | ADORA2AADORA3L3MBTL1KMT2AMEN1 | |
| SCHEMBL7016051 | 0.74 | LRRK2 (0.42) | L3MBTL1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1443181 | 0.72 | KMT2A (0.35) | KMT2AMEN1ALDH1A1MAPTRAB9A | |
| SCHEMBL1443035 | 0.69 | TSHR (0.39) | KMT2AMEN1ALDH1A1MAPTRAB9A | |
| SCHEMBL18471650 | 0.68 | MEN1 (0.31) | L3MBTL1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL10316629 | 0.67 | ADORA1 (0.31) | ADORA2AADORA1BRD4 | |
| SCHEMBL7019238 | 0.66 | L3MBTL1 (0.40) | ADORA2AADORA3L3MBTL1KMT2AMEN1 | |
| SCHEMBL14180415 | 0.63 | KMT2A (0.51) | ADORA2AADORA3L3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9481675-B2 | Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| EP-2475666-A2 | GYRASE INHIBITORS | Trius Therapeutics, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011032050-A2 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | ADORA2A 4802/4885ADORA3 3436/4885L3MBTL1 1004/4885 |
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | ADORA2A 4802/4885ADORA3 3436/4885L3MBTL1 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.